Altamira Therapeutics Ltd. (CYTOF)

Market Cap	440.66K
Revenue (ttm)	n/a
Net Income (ttm)	-8.46M
Shares Out	5.72M
EPS (ttm)	-2.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,500
Average Volume	6,174
Open	0.0700
Previous Close	0.0700
Day's Range	0.0700 - 0.0950
52-Week Range	0.0500 - 2.4700
Beta	2.76
RSI	47.14
Earnings Date	Apr 17, 2025

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: CYTOF